Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2020

Revenues for the three and nine months ended September 30, 2020 and 2019 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Product revenue	$	94,029	$	69,419	$	257,521	$	200,701
Royalty and other income		31		26		91		70

Total revenue	$	94,060	$	69,445	$	257,612	$	200,771

Revenue from Significant Customers

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Cytiva (formerly GE Healthcare)		N/A		N/A		N/A	$	23,759
MilliporeSigma		N/A	$	9,458	$	29,387	$	28,354

Summary of Receivables and Deferred Revenue from Contracts with Customers

The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands):


	2020
Balances from contracts with customers only:
Accounts receivable	$	55,830
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	$	10,141
Revenue recognized during the nine-month period ended September 30, 2020 relating to:
The beginning deferred revenue balance	$	3,133
Changes in pricing related to products or services satisfied in previous periods	$	—